We are excited to announce that our partner, @Veru, Inc., is using Laxxon Medical’s proprietary SPID-Technology platform to develop a new modified-release oral formulation of enobosarm aimed at managing chronic weight loss. Laxxon is excited to share that this formulation is moving forward into clinical studies. This highlights how our technology empowers pharmaceutical partners to create differentiated, high-value therapeutics with significant commercial potential. For more information; read the press announcement: https://lnkd.in/gQcVdrxM
About us
Laxxon is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. From common pharmaceutical drugs to new drug developments, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners, healthcare providers, and patients. Laxxon’s diverse product pipeline is continuously growing and consists of 13 in-house Advanced Patented Generics, in addition to multiple ongoing working-projects with notable pharmaceutical players, biotech organizations and research universities. Innovate with us. www.laxxonmedical.com
- Website
-
http://www.laxxonmedical.com
External link for Laxxon Medical
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Specialties
- Advanced Patented Generics, Patent Extension, Technology Transfer, Research & Development, Commercialization, New Drug Development, 3D Screen Printing, Additive Manufacturing, 505(b)(2), Heterogeneous Distribution, Sequential Release, and Co-Development
Locations
-
Primary
Get directions
12 E 49th St
New York, NY 10017, US
-
Get directions
Laxxon Medical GmbH Hans-Knöll-Str. 6
Jena, D-07745, DE
-
Get directions
6 The Circle
Zurich, 8058, CH
Employees at Laxxon Medical
-
Hikmete O’Brien
Finance & Business |Interim Management, GAAP, and Project Management | Leveraging Financial Expertise, Entrepreneurship, and Corporate Leadership…
-
Rich Ferrante, CPA
Senior Manager, Accounting and Financial Reporting at Laxxon Medical
-
Pascal Zeymer
Incentive and Event Manager
-
Alexander Ruckdaeschel
Chief Strategy Officer at Laxxon Medical
Updates
-
As #BIO2025 draws to a close, we are very grateful for the opportunity to meet with colleagues, share insights, and offer solutions to some of today’s biggest challenges in drug development. www.laxxonmedical.com
-
-
We are at #BIO2025 to help the industry discover innovative, sustainable solutions to navigate these transitions. www.laxxonmedical.com
-
-
How do you differentiate a GLP-1 therapy? At #BIO2025, we are proud to introduce an innovative oral GLP-1 agonist developed specifically for weight loss. Our once-daily, multi-compartment micro tablet potentially offers: · Improved bioavailability · Oral convenience over injectables · Patent protection through 2040 Built on our cutting-edge pharmaceutical screen printing platform, this innovation represents a new chapter in metabolic disease management. Join us at @BIO2025 to learn more about our pipeline and pharmaceutical printing technology. www.laxxonmedical.com
-
We are proud to be at the forefront of using innovation to address one of the key challenges in Parkinson’s care: the limitations of traditional oral therapies. We’re at #BIO2025 and looking forward to discussing our novel sequential release technology, which is used in our innovative oral therapy, specifically indicated for treating “off-periods” in Parkinson’s disease. Through sequential release, we have seen impressive bioavailability versus immediate-release treatments, which means potentially a reduction in dyskinesias. #ParkinsonsResearch #PharmaInnovation #DrugDelivery
-
Exploring the shift from injectables to oral formulations? Interested in the potential of multi-compartment micro tablet technology or the challenges of pH balancing in solid dosage forms? Meet the @Laxxon Medical leadership team at the Biotechnology Innovation Organization's International Convention in Boston next week to learn how our 3D screen printing drug delivery platform and innovative formulation strategies are redefining what's possible in pharmaceutical development. Our capabilities can potentially increase bioavailability by over 350% through sequential release. Let’s connect to discuss how we can support your R&D and commercialization goals. Visit us at @www.laxxonmedical.com #BIO2025 #PharmaInnovation
-
From concept to clinic, successful drug development requires the right partner. Together with our CDMO partner Adare Pharma Solutions, we are developing and manufacturing advanced oral dosage forms to unlock clinical and commercial opportunities across the world. Whether you're advancing a new compound, optimizing an existing one, or interested in Laxxon's in-house Advanced Generics pipeline, let's explore how a partnership with us could accelerate your success. www.laxxonmedical.com #InnovateWithUs #DrugDevelopment #PharmaceuticalIndustry #HealthcareInnovation #DrugDiscovery #Biopharma #Pharmacokinetics #Formulation #OralDrugDelivery #DrugDeliveryInnovation #PharmaInnovation #3DSP
-
-
Not only has Laxxon been able to transform the traditionally injected GLP-1 receptor agonist into a solid oral dosage form, but we have also achieved LXM.2 in micro-tablet form. With our micro-tableting capabilities, Laxxon can offer unique advantages over traditional dosage forms: ➡️ Enhanced Bioavailability: Overcomes challenges of poorly soluble APIs by increasing surface area and absorption. ➡️ Controlled Release Profiles: Multi-compartment designs allow tailored therapeutic effects and minimized side effects. ➡️ Flexible Administration Options: Sprinkle formulations improve dosing convenience and compliance, particularly for children, the elderly, and patients with swallowing difficulties. Learn more about LXM.2 and Laxxon's micro-tableting platform with Laxxon’s COO Klaus Kühne: #InnovateWithUs #IntelligentMedicine #LaxxonMedical #MicroTablets #DrugDelivery #AdditiveManufacturing #LXM2 #GLP1 #Semaglutide